- Home
- IOT vs RPRX Comparison
IOT vs RPRX Comparison
Compare IOT & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IOT | RPRX |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3B | 25.9B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IOT | RPRX |
|---|---|---|
| Price | $38.65 | $60.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $45.42 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 6.1M | 2.7M |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | ★ 92.86 | N/A |
| EPS | 0.10 | ★ 0.71 |
| Revenue | $1,618,635,000.00 | ★ $2,378,193,000.00 |
| Revenue This Year | $23.00 | $38.63 |
| Revenue Next Year | $19.69 | $4.73 |
| P/E Ratio | $499.63 | ★ $85.34 |
| Revenue Growth | ★ 29.57 | 5.06 |
| 52 Week Low | $23.38 | $34.63 |
| 52 Week High | $47.47 | $64.38 |
Technical Indicators
Market Signals| Indicator | IOT | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 49.24 |
| Support Level | $28.31 | $55.66 |
| Resistance Level | $39.20 | N/A |
| Average True Range (ATR) | 2.19 | 1.30 |
| MACD | -0.27 | -0.16 |
| Stochastic Oscillator | 23.70 | 31.48 |
Price Performance
Historical ComparisonAbout IOT Samsara Inc.
Samsara Inc provides an end-to-end solution for operations. The company's Connected Operations Platform consolidates data from its IoT devices and a growing ecosystem of connected assets and third-party systems, and makes it easy for organizations to access, analyze, and act on data insights using its cloud dashboard, custom alerts and reports, mobile apps, and workflows. The company derives almost all of its revenue from subscription services. Geographically, it derives a majority of its revenue from the United States. The company's customers range from small and medium-sized businesses to state and local governments.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.